

PRODUCT INFORMATION

| | |
|---|--|
| Clone ID | DMC393 |
| Target | IL5RA |
| Synonyms | IL5Ra;CD125;IL-5 R alpha |
| Host Species | Rabbit |
| Description | Biotinylated Anti-IL5RA antibody(DMC393); IgG1 Chimeric mAb |
| Delivery | 2-3 weeks |
| Uniprot ID | Q01344 |
| IgG type | Rabbit/Human Fc chimeric IgG1 |
| Clonality | Monoclonal |
| Reactivity | Human |
| Applications | Flow Cyt |
| Recommended Dilutions | Flow Cyt 1:100 |
| Purification | Purified from cell culture supernatant by affinity chromatography |
| Formulation & Reconstitution | Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution. |
| Storage & Shipping | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. |
| Background | The protein encoded by this gene is an interleukin 5 specific subunit of a heterodimeric cytokine receptor. The receptor is comprised of a ligand specific alpha subunit and a signal transducing beta subunit shared by the receptors for interleukin 3 (IL3); colony stimulating factor 2 (CSF2:GM-CSF); and interleukin 5 (IL5). The binding of this protein to IL5 depends on the beta subunit. The beta subunit is activated by the ligand binding; and is required for the biological activities of IL5. This protein has been found to interact with syndecan binding protein (syntenin); which is required for IL5 mediated activation of the transcription factor SOX4. Several alternatively spliced transcript variants encoding four distinct isoforms have been reported. |
| Usage | Research use only |
| Conjugate | Biotinylated |
| DIMA Disclaimer | All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement. |

